Fresenius Kabi SwissBioSim GmbH et al. vs Regeneron Pharmaceuticals, Inc. - IPR2025-01268

Explore the PTAB proceeding IPR2025-01268 filed by Fresenius Kabi SwissBioSim GmbH et al. against Regeneron Pharmaceuticals, Inc. on Jul 14, 2025. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number
IPR2025-01268
Filing Date
Jul 14, 2025
Petitioner
Fresenius Kabi SwissBioSim GmbH et al.
Respondent
Regeneron Pharmaceuticals, Inc.
Status
Pending
Respondent Application Number
16739559
Respondent Tech Center
1600
Respondent Patent Number
11084865

Proceeding Decision New

Decision documents related to this case provide insights into the outcomes of proceedings. These documents are crucial for understanding the legal determinations and implications for the parties involved.

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.

Document NameFiling DateCategoryFiling Party

Alert me when new update on this case

Regeneron's Preliminary Patent Owner Response (IPR2025-01268)

Oct 24, 2025PAPERPATENT OWNER

Zaltrap® Label

Oct 24, 2025EXHIBITPATENT OWNER

Regeneron v. Mylan, 22-cv-61, Trial Transcript (Public Excerpts) (N.D.W. Va.)

Oct 24, 2025EXHIBITPATENT OWNER

J.L. Fast et al., Physical Instability of a Therapeutic Fc Fusion Protein: Domain Contributions to Conformational and Colloidal Stability, 48 BIOCHEM. 11724 (2009) (“Fast”)

Oct 24, 2025EXHIBITPATENT OWNER

Regeneron v. Mylan, 22-cv-61, Trial Ex. DTX-3619A, Fusion Proteins Disclosed in Papadopoulos

Oct 24, 2025EXHIBITPATENT OWNER

International Publication No. WO 00/75319 (“WO 00/75319”)

Oct 24, 2025EXHIBITPATENT OWNER

U.S. Patent Application Pub. No. 2006/0058234 A1 (“Daly”)

Oct 24, 2025EXHIBITPATENT OWNER

W. Wang, Protein Aggregation and Its Inhibition in Biopharmaceutics, 289 INT. J. PHARM. 1 (2005) (“Wang 2005”)

Oct 24, 2025EXHIBITPATENT OWNER

J. Gaudreault et al., Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration, 46(2) INVEST OPHTHALMOL VIS SCI. 726 (2005) (“Gaudreault”)

Oct 24, 2025EXHIBITPATENT OWNER

Thomas et al., Comparative Effectiveness of Aflibercept for the Treatment of Patients with Neovascular Age-Related Macular Degeneration, 7 CLINICAL OPHTHALMOLOGY 495 (2013) (“Thomas”)

Oct 24, 2025EXHIBITPATENT OWNER

International Publication No. WO 2005/102303 A2 (“Peyman”)

Oct 24, 2025EXHIBITPATENT OWNER

M.R. Marmour, Retinal detachment from hyperosmotic intravitreal injection, 18(12) INVEST OPHTHALMOL VIS SCI. 1237 (1979) (“Marmour ”)

Oct 24, 2025EXHIBITPATENT OWNER

Declaration of Kenneth S. Graham, dated April 18, 2024

Oct 24, 2025EXHIBITPATENT OWNER

Excerpts of File History of U.S. Patent No. 11,084,865

Oct 24, 2025EXHIBITPATENT OWNER

Petitioner's Opposition to Patent Owner's Request for Discretionary Denial

Oct 23, 2025PAPERPETITIONER

Ex. 1009

Oct 23, 2025EXHIBITPETITIONER

Ex. 1010

Oct 23, 2025EXHIBITPETITIONER

Ex. 1011

Oct 23, 2025EXHIBITPETITIONER

Patent Owner's Discretionary Denial Brief

Sep 23, 2025PAPERPATENT OWNER

Mylan Redacted Trial Decision, 22-cv-61, Dkt. 692 (N.D.W. Va.)

Sep 23, 2025EXHIBITPATENT OWNER

SB Redacted PI Decision, 24-md-3103, Dkt. 194 (N.D.W. Va.)

Sep 23, 2025EXHIBITPATENT OWNER

Formycon Redacted PI Decision, 24-md-3103, Dkt. 247 (N.D.W. Va.)

Sep 23, 2025EXHIBITPATENT OWNER

Celltrion Redacted PI Decision, 24-md-3103, Dkt. 248 (N.D.W. Va.)

Sep 23, 2025EXHIBITPATENT OWNER

SB Appeal Decision, 24-1965, Dkt. 76 (Fed. Cir.)

Sep 23, 2025EXHIBITPATENT OWNER

Formycon Appeal Decision, 24-2009, Dkt. 67 (Fed. Cir.)

Sep 23, 2025EXHIBITPATENT OWNER

Celltrion Appeal Decision, 24-2058, Dkt. 62 (Fed. Cir.)

Sep 23, 2025EXHIBITPATENT OWNER

Fresenius, Fresenius to Expand Biopharma Portfolio with a New Licensing Agreement to Commercialize a Proposed Aflibercept Biosimilar (Dec. 20, 2024), https://www.fresenius.com/node/6982

Sep 23, 2025EXHIBITPATENT OWNER

Email from D. Berl to S. Gibson re Scheduling Conference (Sept. 12, 2025)

Sep 23, 2025EXHIBITPATENT OWNER

Notice: Power of Attorney

Aug 4, 2025PAPERPATENT OWNER

Notice: Mandatory Notice

Aug 4, 2025PAPERPATENT OWNER

Notice: Notice filing date accorded

Jul 23, 2025PAPERBOARD

Petitioner Fresenius Kabi SwissBiosim, GmBH Power of Attorney

Jul 14, 2025PAPERPETITIONER

Fresenius Kabi SwissBiosim, GmBH Petition for IPR of USP11,084,865

Jul 14, 2025PAPERPETITIONER

Ex. 1001

Jul 14, 2025EXHIBITPETITIONER

Ex. 1002

Jul 14, 2025EXHIBITPETITIONER

Ex. 1003

Jul 14, 2025EXHIBITPETITIONER

Ex. 1004

Jul 14, 2025EXHIBITPETITIONER

Ex. 1005

Jul 14, 2025EXHIBITPETITIONER

Ex. 1006

Jul 14, 2025EXHIBITPETITIONER

Ex. 1007

Jul 14, 2025EXHIBITPETITIONER

Ex. 1008

Jul 14, 2025EXHIBITPETITIONER